Tonix Pharmaceuticals, a biopharmaceutical company with a diverse development pipeline, will participate in the World Vaccine Congress Washington 2025. The event, scheduled for April 22-24 in Washington, D.C., will provide a platform for the company to share its latest scientific research and insights.
The presentation is significant as it will showcase Tonix's ongoing work in developing innovative medical solutions. The company is currently focused on multiple critical areas of research, including pain management, public health challenges, and pharmaceutical development.
Of particular note is Tonix's imminent plan to submit a New Drug Application to the FDA for TNX-102 SL, a product candidate for fibromyalgia management. The drug has already completed two statistically significant phase 3 studies and received Fast Track designation from the FDA.
The company's research extends beyond fibromyalgia treatment. A recent contract from the U.S. Department of Defense, worth up to $34 million over five years, will support the development of TNX-4200, a broad-spectrum antiviral agent designed to improve medical readiness in biological threat environments.
Tonix's diverse portfolio includes research in central nervous system disorders, immunology, rare diseases, and infectious diseases. The company also commercially markets migraine treatments through its subsidiary, Tonix Medicines.
The upcoming presentation at the World Vaccine Congress represents an opportunity for Tonix to demonstrate its commitment to advancing medical research and developing innovative therapeutic solutions.
